Abstract:Objective To study the clinical features and antifungal therapeutic effects in nonacquired immune deficiency syndrome(AIDS)patients with cryptococcal meningitis. Methods One hundred and fifty-four non-AIDS patients with cryptococcal meningitis admitted to Huashan Hospital, Fudan University from 1997 to 2007 were reviewed retrospectively. Clinical characteristics, initial antifungal therapies and outcome of these patients were analyzed. Continuous variables were analyzed using t test and categorical variables were compared by X~2 test or Fisher's exact test. Kaplan-Meier survival curves of different therapies were compared with log-rank test. Results Fifty-one patients (33.12%)had one or more predisposing factors. Headache, fever, meningeal irritation, vomiting and altered mental status were common clinical symptoms and signs during the course of diseases. The positive rates of cerebrospinal fluid(CSF)smear, CSF culture and detection of CSF cryptococcal capsular polysaccharide antigen were 88.44%,78.95%and 100.00%,respectively.Twelve cases were excluded because treatment durations were less than 7 days, including 9 died,2 discharged against medical advice due to illness exacerbation and 1 lost after against medical advice discharge. The remaining 142 patients were evaluated for therapeutic effects. The effective rates in amphotericin B (AmB)group, fluconazole group and AmB plus fluconazole group were 78.3%(36/46),33.3%(8/24)and 76.0%(38/50),respectively. The therapeutic effects in AmB group and AmB plus fluconazole group were superior to fluconazole group(X~2=13.6354,12.5509;P＜0.01).Eleven patients were lost during 1-year follow-up. The attributable and overall mortality in the remaining 143 patients were 19.58% and 28.67%,respectively.The 1-year survival rates in AmB group and AmB plus fluconazole group were significantly higher than that in fluconazole group. Conclusions The mortality of non-AIDS cryptococcal meningitis is still high,which is closely correlated with initial antifungal therapies. AmB alone or combined with flucytosine is related to both higher successful response and higher survival rate, while the efficacy of initial fluconazole alone or combined with flucytosine is poor.

Clinical Research of Fungal Infection in 296 AIDS Patients

Clinical Analysis of 35 Cases of AIDS with Invasive Fungal Infection

Species distribution and antifungal susceptibility of Candida sp. isolates from AIDS patients with oropharyngeal candidiasis

Study on drug resistance of fungi isolated from infected patients in hospital

Clinical Distribution and Drug Sensitivity of 486 Strains of Candida in 1,690 Specimens

Clinical features and antifungal therapeutic effects of 154 patients with cryptococcal meningitis

Antifungal Susceptibilities of Cryptococcus Species Complex Isolates from AIDS and Non-Aids Patients in Southeast China

Clinical Fungal Infections and Their Drug Resistance

Genotyping and Antifungal Susceptibility of Candida Albicans Isolates from AIDS Patients

Clinical Analysis of Respiratory Tract Fungal Infection.

Clinical analysis of cryptococcal meningitis:21 cases

Analysis of antifungal susceptibility in vitro and fungi distribution in clinics

Study on antifungal susceptibilities and resistance trends of 209 strains of C. albicans with various genotypes and filamentous fungi isolated from clinical specimens

Clinical Retrospective Analysis of 69 Patients with Fungemia

In Vitro Antidrug Susceptibility Testing of Candida Species Isolated from Aseptic Body Fluids

Retrospective analysis of 130 cases of deep fungal infection in blood samples: fungus identification and drug sensitive test

Clinical analysis of 14 cases of candidemia

Clinical Distribution and Drug Resistance Analysis of 978 Clinical Fungus Strains

Species identification and antifungal susceptibility of 128 strains of yeast fungi

Invasive fungal infections among inpatients with acquired immune deficiency syndrome at a Chinese university hospital.

Analysis of clinical speciality of invasive fungai infection on 137 cases